See more : GeckoSystems International Corporation (GOSY) Income Statement Analysis – Financial Results
Complete financial analysis of NextCure, Inc. (NXTC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NextCure, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Centaur Media Plc (CAU.L) Income Statement Analysis – Financial Results
- Liontrust Asset Management PLC (LIO.L) Income Statement Analysis – Financial Results
- Silver Valley Metals Corp. (SVMFF) Income Statement Analysis – Financial Results
- MFEC Public Company Limited (MFEC.BK) Income Statement Analysis – Financial Results
- Bactiguard Holding AB (publ) (0QV2.L) Income Statement Analysis – Financial Results
NextCure, Inc. (NXTC)
About NextCure, Inc.
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 22.38M | 6.35M | 0.00 | 0.00 |
| Cost of Revenue | 3.68M | 4.48M | 4.30M | 46.55K | 34.22K | 1.68M | 582.00K |
| Gross Profit | -3.68M | -4.48M | -4.30M | 22.33M | 6.31M | -1.68M | -582.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 99.79% | 99.46% | 0.00% | 0.00% |
| Research & Development | 47.93M | 54.20M | 50.19M | 46.55M | 34.22M | 19.79M | 12.95M |
| General & Administrative | 19.71M | 21.71M | 20.57M | 17.05M | 9.61M | 3.41M | 2.60M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.71M | 21.71M | 20.57M | 17.05M | 9.61M | 3.41M | 2.60M |
| Other Expenses | 0.00 | 1.18M | 1.38M | 4.62M | 3.75M | 397.00K | 80.00K |
| Operating Expenses | 67.64M | 75.91M | 70.77M | 63.60M | 43.83M | 23.20M | 15.55M |
| Cost & Expenses | 67.64M | 75.91M | 70.77M | 63.60M | 43.83M | 23.20M | 15.55M |
| Interest Income | 0.00 | 1.17M | 1.32K | 4.55K | 3.75K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 77.00K | 183.00K | 209.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 3.68M | 4.48M | 4.30M | 3.41M | 2.69M | 1.68M | 582.00K |
| EBITDA | -59.04M | -70.25M | -65.01M | -37.81M | -34.79M | -21.10M | -14.97M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -184.22% | -548.20% | 0.00% | 0.00% |
| Operating Income | -67.64M | -75.91M | -70.77M | -41.23M | -37.48M | -23.20M | -15.55M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -184.22% | -590.55% | 0.00% | 0.00% |
| Total Other Income/Expenses | 4.91M | 1.18M | 1.38M | 4.62M | 3.75M | 397.00K | 80.00K |
| Income Before Tax | -62.72M | -74.73M | -69.39M | -36.60M | -33.74M | -22.80M | -15.47M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -163.57% | -531.54% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -5.30M | 6.96M | -3.41M | 2.52M | 397.00K | 0.00 |
| Net Income | -62.72M | -69.43M | -69.39M | -33.19M | -33.74M | -22.80M | -15.47M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -148.32% | -531.54% | 0.00% | 0.00% |
| EPS | -2.25 | -2.50 | -2.51 | -1.21 | -2.15 | -2.27 | -1.54 |
| EPS Diluted | -2.25 | -2.50 | -2.51 | -1.21 | -2.15 | -2.27 | -1.54 |
| Weighted Avg Shares Out | 27.84M | 27.74M | 27.62M | 27.53M | 15.70M | 10.04M | 10.04M |
| Weighted Avg Shares Out (Dil) | 27.84M | 27.74M | 27.62M | 27.53M | 15.70M | 10.04M | 10.04M |
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.04%
Legal & General Group Plc Decreases Position in NextCure Inc (NASDAQ:NXTC)
NextCure Inc (NASDAQ:NXTC) Shares Sold by JPMorgan Chase & Co.
Wellington Management Group LLP Reduces Position in NextCure Inc (NASDAQ:NXTC)
The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant
7 High-Risk Stocks For Market Gamblers
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
Goldman Sachs Group Inc. Buys 6,741 Shares of NextCure Inc (NASDAQ:NXTC)
Bank of New York Mellon Corp Has $2.49 Million Holdings in NextCure Inc (NASDAQ:NXTC)
NextCure (NXTC) Gets a Buy Rating from Morgan Stanley
Source: https://incomestatements.info
Category: Stock Reports